Physician
Hematology
Dr. Ronald G. Stoller, MD
|
|
Give Review
Ronald Stoller is an expert in the field of Hematology. He attended Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School has a rank of 1 in research and a 12 in primary care He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Ronald G. Stoller, MD is a published doctor and has 15 publications published. The lastest was: 'A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors.' Dr. Ronald G. Stoller accepts all Medicare patients.
Publications
- A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors.
- Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers.
- Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.
- Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic Cancer.
- A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid Cancers: a ...
- Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
- Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced Colorectal Cancer.
- Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies.
- Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
- Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
- A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
- Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
- Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced Cancers.
- Final results of a placebo-controlled study of filgrastim in small-cell lung Cancer: exploration of risk factors for febrile neutropenia.
Schools
Harvard Medical School
Peter Bent Brigham Hospital
Nci
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1205800877 | |
| NPPES Provider LastName | STOLLER | |
| NPPES Provider FirstName | RONALD | |
| NPPES Provider ZIPCode | 152321301 | |
| NPPES Provider State | PA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 417.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 3.84 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1205800877 |
| Last Name Of The Provider | STOLLER |
| First Name Of The Provider | RONALD |
| View All |
Similar Doctors
|
|
Dr. Barry C. Lembersky, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Peter G. Ellis, MD |
|
|
Dr. Rafic J. Farah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David P. Shreiner, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Mark A. Socinski, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Swapna Goday, MD |
|
|
Dr. John N. Robinson, MD |
|
|
Dr. Vida A. Passero, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. T Clark Gamblin, MD |